OncoMatch/Clinical Trials/NCT04669171
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Is NCT04669171 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including EO2463 and rituximab for follicular lymphoma.
Treatment: EO2463 · lenalidomide · rituximab — The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Endocrine / hormonal
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any systemic therapy
have received at least one prior line of treatment
Cannot have received: EO2463 (EO2463)
prior exposure to EO2463
Cannot have received: immunotherapy (immunostimulatory or immunosuppressive therapy)
immunotherapy (meaning immunostimulatory or immunosuppressive therapy; beside excluded, or allowed, compounds per other inclusion/exclusion criteria specifications)
Cannot have received: radionuclide therapy
radionuclide therapy
Cannot have received: radiotherapy
Exception: radiotherapy as only prior treatment is allowed in newly diagnosed, previously untreated cohorts
radiotherapy
Cannot have received: cytoreductive therapy
cytoreductive therapy
Cannot have received: investigational agent
treatment with any other investigational agent within 28 days before the first EO2463 administration
Cannot have received: rituximab or other B cell ablation therapy
received rituximab or other B cell ablation therapy within 8 weeks of start of study treatment
Cannot have received: CAR T-cell therapy
Exception: exclusion only if progressed within 6 months after this therapy
received prior CAR T-cell therapy and progressed within 6 months after this therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana Farber Cancer Institute · Boston, Massachusetts
- Mayo Clinic · Rochester, Minnesota
- University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) · Rochester, New York
- University of Washington-Seattle Cancer Care Alliance · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04669171 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior EO2463, immunotherapy (immunostimulatory or immunosuppressive therapy), radionuclide therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages